A phase I trial was initiated with the pan-HER inhibitor afatinib plus the MEK inhibitor selumetinib in 19 CRC patients with KRAS and PIK3CA wild-type mutations. The gene discussed is PIK3CA; the disease is colorectal carcinoma.